About this program

IPH5401 is a first-in-class therapeutic antibody that specifically binds and blocks C5a receptors (C5aR) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. Part of the innate immune system, these types of cells promote tumor growth by secreting inflammatory and angiogenic factors. They potently suppress T and NK cells and hamper the activities of PD-1 checkpoint blockers.

C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSC and neutrophils in the tumor microenvironment. 

IPH5401 is a fully human antibody that blocks the binding of C5a to C5aR, thereby reducing the accumulation and activation of MDSC and neutrophils in tumors. Treatment with IPH5401 may unleash anti-tumor activities of T cells and NK cells. Preclinical experiments support development of IPH5401 as single agent and in combination with PD-1 checkpoint blockers or other cancer immunotherapies.

Innate Pharma acquired full worldwide exclusive rights to develop and commercialize the anti-C5aR antibody from Novo Nordisk A/S in July 2017.

In January 2018, Innate Pharma and AstraZeneca/MedImmune entered into a clinical trial collaboration to evaluate the combination of IPH5401 and durvalumab (anti-PD-L1) in a Phase I/II study for patients with selected solid tumors.

Mechanism of action of IPH5401